CY1122563T1 - ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt - Google Patents
ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγtInfo
- Publication number
- CY1122563T1 CY1122563T1 CY20201100049T CY201100049T CY1122563T1 CY 1122563 T1 CY1122563 T1 CY 1122563T1 CY 20201100049 T CY20201100049 T CY 20201100049T CY 201100049 T CY201100049 T CY 201100049T CY 1122563 T1 CY1122563 T1 CY 1122563T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amide substituted
- substituted thiazoles
- compound
- rorγt modulators
- rorγt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του Τύπου I, όπου: R1, R2, R3, R5, Α1, Α2 και ορίζονται στην προδιαγραφή. Η εφεύρεση περιλαμβάνει επίσης ένωση του Τύπου I για χρήση σε μέθοδο θεραπείας ή βελτίωσης συνδρόμου, διαταραχής ή νόσου, όπου το σύνδρομο, η διαταραχή ή η νόσος είναι ρευματοειδής αρθρίτιδα ή ψωρίαση. Η εφεύρεση περιλαμβάνει επίσης ένωση για χρήση σε μέθοδο διαμόρφωσης της δραστικότητας RORγt σε ένα θηλαστικό με χορήγηση μιας θεραπευτικός αποτελεσματικής ποσότητας μιας τουλάχιστον ενώσεως της αξίωσης 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072599P | 2014-10-30 | 2014-10-30 | |
PCT/US2015/058200 WO2016069978A1 (en) | 2014-10-30 | 2015-10-30 | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122563T1 true CY1122563T1 (el) | 2021-01-27 |
Family
ID=54542554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100049T CY1122563T1 (el) | 2014-10-30 | 2020-01-21 | ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt |
Country Status (21)
Country | Link |
---|---|
US (1) | US9845319B2 (el) |
EP (1) | EP3212642B1 (el) |
JP (1) | JP6695335B2 (el) |
KR (1) | KR20170075787A (el) |
CN (1) | CN108064224B (el) |
AU (1) | AU2015339091B2 (el) |
BR (1) | BR112017008852A2 (el) |
CA (1) | CA2965518A1 (el) |
CY (1) | CY1122563T1 (el) |
DK (1) | DK3212642T3 (el) |
ES (1) | ES2767303T3 (el) |
HK (1) | HK1243418A1 (el) |
HR (1) | HRP20200016T1 (el) |
HU (1) | HUE046888T2 (el) |
IL (1) | IL251857B (el) |
MA (1) | MA40865B1 (el) |
PL (1) | PL3212642T3 (el) |
PT (1) | PT3212642T (el) |
RS (1) | RS59752B1 (el) |
SI (1) | SI3212642T1 (el) |
WO (1) | WO2016069978A1 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3212641T (pt) | 2014-10-30 | 2019-02-11 | Janssen Pharmaceutica Nv | Tiazoles como moduladores de rorãt |
JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
JP2021517563A (ja) | 2018-03-12 | 2021-07-26 | エスカリア バイオサイエンシーズ,ビーブイ | 二環式RORγモジュレーター |
WO2019177997A1 (en) | 2018-03-12 | 2019-09-19 | Escalier Biosciences B.V. | Spirocyclic ror-gamma modulators |
CN112566901A (zh) * | 2018-06-18 | 2021-03-26 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基取代的吡唑类 |
CA3103771A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
JP2021529161A (ja) | 2018-06-18 | 2021-10-28 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレーターとしてのピリジニルピラゾール |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
AU2019289223B2 (en) * | 2018-06-18 | 2023-09-21 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
CA2195847A1 (en) | 1994-07-27 | 1996-02-08 | John J. Talley | Substituted thiazoles for the treatment of inflammation |
CN101519386A (zh) | 2001-04-16 | 2009-09-02 | 田边三菱制药株式会社 | 高传导率钙-活化k通道开启剂 |
IL160327A0 (en) * | 2001-08-13 | 2004-07-25 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
DE60208815T2 (de) * | 2001-10-12 | 2006-07-20 | Bayer Pharmaceuticals Corp., West Haven | Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit |
WO2006124687A1 (en) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
TWI444370B (zh) | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
EP2583557B1 (de) | 2008-07-17 | 2016-01-13 | Bayer CropScience AG | Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel |
AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
US9101600B2 (en) | 2010-03-11 | 2015-08-11 | New York University | Compounds as RORγt modulators and uses thereof |
HUE040420T2 (hu) | 2010-03-11 | 2019-03-28 | Univ New York | Amidvegyületek, mint RORyT modulátorok és felhasználásuk |
WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
US9505798B2 (en) | 2010-11-29 | 2016-11-29 | New York University | Steroid compounds as RORyt modulators and uses thereof |
EP2660597B1 (en) | 2010-12-28 | 2017-09-13 | ARKRAY, Inc. | Method for determining condition of oral cavity and analytical tool, apparatus and program used for the method |
US9012651B2 (en) | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
EP2738170B1 (en) | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
RU2014113926A (ru) | 2011-09-09 | 2015-10-20 | Нью Йорк Юниверсити | АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ |
JP5918859B2 (ja) | 2011-12-02 | 2016-05-18 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体RARに関連するオーファン受容体−ガンマ(RORγ、NR1F3)活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド |
US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
SG11201407919WA (en) | 2012-05-31 | 2014-12-30 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | RORγ調節因子 |
US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
WO2015042212A1 (en) | 2013-09-20 | 2015-03-26 | Bristol-Myers Squibb Company | RORγ MODULATORS |
MY179106A (en) | 2013-12-05 | 2020-10-28 | Lead Pharma Holding Bv | Ror gamma (rory) modulators |
WO2015103510A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Heterocyclic sulfone as ror-gamma modulators |
EP3092229B1 (en) | 2014-01-06 | 2018-03-28 | Bristol-Myers Squibb Company | Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators |
WO2015103508A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | CARBOCYCLIC SULFONE RORγ MODULATORS |
US9708253B2 (en) | 2014-01-06 | 2017-07-18 | Bristol-Myers Squibb Company | Cyclohexyl sulfone RORγ modulators |
CA2942871A1 (en) | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
CN103833672A (zh) * | 2014-03-28 | 2014-06-04 | 中国药科大学 | 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法 |
-
2015
- 2015-10-30 MA MA40865A patent/MA40865B1/fr unknown
- 2015-10-30 US US14/927,502 patent/US9845319B2/en active Active
- 2015-10-30 PL PL15794729T patent/PL3212642T3/pl unknown
- 2015-10-30 JP JP2017523349A patent/JP6695335B2/ja not_active Expired - Fee Related
- 2015-10-30 KR KR1020177014656A patent/KR20170075787A/ko not_active Application Discontinuation
- 2015-10-30 PT PT157947292T patent/PT3212642T/pt unknown
- 2015-10-30 HU HUE15794729A patent/HUE046888T2/hu unknown
- 2015-10-30 RS RS20191697A patent/RS59752B1/sr unknown
- 2015-10-30 WO PCT/US2015/058200 patent/WO2016069978A1/en active Application Filing
- 2015-10-30 CA CA2965518A patent/CA2965518A1/en not_active Abandoned
- 2015-10-30 BR BR112017008852-5A patent/BR112017008852A2/pt not_active Application Discontinuation
- 2015-10-30 ES ES15794729T patent/ES2767303T3/es active Active
- 2015-10-30 DK DK15794729T patent/DK3212642T3/da active
- 2015-10-30 AU AU2015339091A patent/AU2015339091B2/en not_active Ceased
- 2015-10-30 SI SI201530992T patent/SI3212642T1/sl unknown
- 2015-10-30 CN CN201580072012.8A patent/CN108064224B/zh active Active
- 2015-10-30 EP EP15794729.2A patent/EP3212642B1/en active Active
-
2017
- 2017-04-23 IL IL251857A patent/IL251857B/en not_active IP Right Cessation
-
2018
- 2018-03-02 HK HK18103051.0A patent/HK1243418A1/zh unknown
-
2020
- 2020-01-07 HR HRP20200016TT patent/HRP20200016T1/hr unknown
- 2020-01-21 CY CY20201100049T patent/CY1122563T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN108064224B (zh) | 2022-03-29 |
HK1243418A1 (zh) | 2018-07-13 |
JP6695335B2 (ja) | 2020-05-20 |
US20160122335A1 (en) | 2016-05-05 |
MA40865B1 (fr) | 2019-11-29 |
KR20170075787A (ko) | 2017-07-03 |
WO2016069978A1 (en) | 2016-05-06 |
AU2015339091B2 (en) | 2020-05-28 |
RS59752B1 (sr) | 2020-02-28 |
AU2015339091A1 (en) | 2017-05-11 |
CA2965518A1 (en) | 2016-05-06 |
DK3212642T3 (da) | 2019-11-25 |
EP3212642B1 (en) | 2019-10-30 |
BR112017008852A2 (pt) | 2018-01-16 |
CN108064224A (zh) | 2018-05-22 |
US9845319B2 (en) | 2017-12-19 |
PL3212642T3 (pl) | 2020-04-30 |
SI3212642T1 (sl) | 2020-01-31 |
PT3212642T (pt) | 2019-12-19 |
IL251857A0 (en) | 2017-06-29 |
ES2767303T3 (es) | 2020-06-17 |
HRP20200016T1 (hr) | 2020-03-20 |
HUE046888T2 (hu) | 2020-03-30 |
JP2018500286A (ja) | 2018-01-11 |
EP3212642A1 (en) | 2017-09-06 |
IL251857B (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122563T1 (el) | ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt | |
CY1119234T1 (el) | Μεθυλενο συνδεδεμενοι κινολινυλ ρυθμιστες του ror-γαμμα-τ | |
CY1121716T1 (el) | Τριφθορομεθυλο αλκοολες ως διαμορφωτες της ror-γαμμα-τ | |
CY1121285T1 (el) | Θειαζολια ως διαμορφωτες toy roryt | |
CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
CY1123569T1 (el) | Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer | |
CY1120834T1 (el) | Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1 | |
CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
CY1122916T1 (el) | Νεες ενωσεις ως ρυθμιστες ror γαμμα | |
GT201500092A (es) | Moduladores de quinolinillo unidos a fenilo de ror-gamma-t | |
CY1124929T1 (el) | 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139 | |
CY1120111T1 (el) | Αντιβακτηριακα παραγωγα 2η-ινδαζολης | |
CY1121362T1 (el) | Παραγωγα της 1,2-διϋδρο-3η- πυρρολo[1,2-c] ιμιδαζολ-3-ονης και η χρηση τους ως αντιβακτηριακοι παραγοντες | |
ECSP18088146A (es) | 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT | |
BR112016008258A2 (pt) | moduladores de ror?t de quinolinila | |
UY36263A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso | |
EA201790327A1 (ru) | Соединения замещенного пиперидина | |
CU20170007A7 (es) | Compuestos de imidazopiridazina | |
EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
CY1120875T1 (el) | Ν-(ετερο)αρυλ-υποκατασταθεντα ετεροκυκλικα παραγωγα χρησιμα για την αγωγη νοσων ή παθησεων που σχετιζονται με το κεντρικο νευρικο συστημα | |
BR112017008594A2 (pt) | derivados de 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida que são úteis para o tratamento de diabetes inter alia |